Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00985426 · ClinicalTrials.gov registry record · Phase 3
Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients
A Phase 3 study of Chronic Kidney Disease, sponsored by Dynavax Technologies Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 521
- Enrollment target
- 1
- Study location
NCT00985426 is a Phase 3 study of Chronic Kidney Disease that has completed, run by Dynavax Technologies Corporation. The registered enrollment target is 521 participants, below the 3,202-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00985426, a Phase 3 study of Chronic Kidney Disease, has completed, sponsored by Dynavax Technologies Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 521 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to demonstrate the safety and immunogenicity of a new investigational hepatitis B virus vaccine, HEPLISAV-B, in patients 18 to 75 years of age who have progressive loss of kidney function.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL HEPLISAV-B
- BIOLOGICAL Engerix-B
Study Locations (1)
Virginia
- Clinical Research Associates of Tidewater - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 521 participants |
| Start Date | 2009-09 |
| Est. Completion | 2012-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00985426
The ClinicalTrials.gov registry entry for NCT00985426 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 521 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,202-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (84% lower). The listed sponsor is Dynavax Technologies Corporation, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Kidney Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00985426 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT00985426 about?
NCT00985426 is a clinical study titled "Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients". The purpose of the study is to demonstrate the safety and immunogenicity of a new investigational hepatitis B virus vaccine, HEPLISAV-B, in patients 18 to 75 years of age who have progressive loss of kidney function.
What is the current status of trial NCT00985426?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 521 participants. The study started on 2009-09. Estimated completion is 2012-01.
What conditions does trial NCT00985426 study?
This clinical trial studies the following conditions: Chronic Kidney Disease.
What interventions are being tested in trial NCT00985426?
The interventions under investigation include: Placebo (OTHER), HEPLISAV-B (BIOLOGICAL), Engerix-B (BIOLOGICAL).
Who is sponsoring clinical trial NCT00985426?
This trial is sponsored by Dynavax Technologies Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00985426 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Patient-driven Management of BP in CKD
RECRUITING · Phase 3
-
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
RECRUITING · Phase 3
-
A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)
RECRUITING · Phase 3
-
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
RECRUITING · Phase 3
-
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
RECRUITING · Phase 3
-
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.